Navigation Links
Plavix's New Generic Status Could Be Boon for Patients
Date:5/15/2012

By Steven Reinberg
HealthDay Reporter

TUESDAY, May 15 (HealthDay News) -- The blockbuster drug Plavix (clopidogrel), used to prevent clotting in some heart patients, will go off patent in the United States on Thursday, making it considerably more affordable.

Adherence rates will improve as a result, and fewer patients will suffer from preventable cardiovascular problems, said Dr. Gregg Fonarow, a professor of medicine and director of the Ahmanson-UCLA Cardiomyopathy Center in Los Angeles.

"This medication has helped millions of patients avoid fatal and non-fatal cardiovascular events," said Fonarow, who also is a spokesman for the American Heart Association. But its high cost has "contributed to patients not filling initial prescriptions for the drug and premature discontinuation of clopidogrel," he said.

Patients who stop taking the drug prematurely may then face catastrophic consequences, including fatal cardiovascular events and strokes, he added.

Plavix works by helping prevent platelets in the blood from sticking together to form clots. The drug usually is taken along with aspirin, which acts as a blood thinner to prevent heart attack and stroke.

Plavix commonly is used by patients with heart-related chest pain, unstable heart disease or those who have had a stent implanted to open a blocked artery.

"The most important impact of the availability of generics will be to reduce costs for patients and health systems where clopidogrel is already indicated," said Dr. Ralph Sacco, chairman of neurology at the University of Miami School of Medicine and former president of the American Heart Association.

The drug doesn't work for everyone, however. Some patients cannot metabolize it, which reduces its effectiveness.

In addition, new drugs are available that may be better than Plavix, Fonarow said.

"Newer antiplatelet agents, such as prasugrel (Effient) and ticagrelor (Brilinta), have been shown to be more [effective] than clopidogrel, and for many patients these [drugs] may be a better choice, despite higher cost," Sacco said.

Sales of Plavix, made by Bristol-Myers Squibb, topped $9 billion in 2011. A generic version, at a much lower cost, is expected to eat into those sales dramatically. The drug already is sold as a generic by Sanofi in much of the European Union, according to the Associated Press.

Plavix currently can cost almost $200 a month, according to published reports. Generic versions are expected to cost much less.

To keep patients using brand-name Plavix rather than a generic version, the manufacturer is offering coupons that will bring down the cost.

Plavix, even in a less expensive version, can't replace other clot-preventing drugs, such as warfarin, in certain patients.

For example, Plavix is not recommended for patients with an irregular heartbeat, called atrial fibrillation, who take blood thinners to prevent strokes. A 2009 report in the New England Journal of Medicine said patients with atrial fibrillation who took Plavix were at an unacceptably high increased risk of severe bleeding.

"For patients with atrial fibrillation, anticoagulants like warfarin (Coumadin), dabigatran (Pradaxa) and rivaroxaban (Xarelto) are indicated, and clopidogrel is not an appropriate substitute," Fonarow said.

More information

For more information on Plavix, visit the U.S. National Institutes of Health.

SOURCES: Ralph Sacco M.D., chairman of neurology, University of Miami Miller School of Medicine, and former president, American Heart Association; Gregg Fonarow, M.D., professor of medicine, director, Ahmanson-UCLA Cardiomyopathy Center, co-director, University of California-Los Angeles Preventative Cardiology Program; Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Generic, Brand-Name Heart Drugs Seem to Have Same Effect on Thyroid
2. Variation in make-up of generic epilepsy drugs can lead to dosing problems
3. Use of $4 generic drug programs could save society billions of dollars, study shows
4. Speedy generic approval may not benefit consumers as much as expected, Rotman model shows
5. Speedy generic approval may not benefit consumers as much as expected, Rotman model shows
6. Generic drug may improve the effectiveness of cancer nanotherapies
7. Disparities in treatment of children in the emergency department based on their insurance status
8. KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
9. Erlotinib dose-adjusted for smoking status effective as first treatment for head and neck cancer
10. IU study: Socioeconomic status more influential than race in determination of child abuse
11. Duration of RBC storage does not affect short-term pulmonary, immunologic, or coagulation status
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Plavix's New Generic Status Could Be Boon for Patients
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... The bar ... glitterati, those unreal icons inhabiting the rarified air of pop and film stardom.(1) Not ... and anyone snapping pictures: the smile. Grins now run the gamut from being encrusted ...
(Date:4/24/2017)... ... 24, 2017 , ... Sean Fay is the undisputed king of the infomercial. ... and the George Foreman Grill (which sold more than 100 million units worldwide), he ... years. , Now, due to changes in the broadcast media landscape, the once ever-present ...
(Date:4/24/2017)... ... April 24, 2017 , ... ALP ... food supplements, announced its popular products are now available for purchase on StackedNutrition.com, ... prioritizes the use of premium natural ingredients in making all of its products. ...
(Date:4/24/2017)... ... April 24, 2017 , ... Salus Telehealth, ... the company’s VideoMedicine mobile platform has launched Quick Care, a new service offering ... Quick Care provides patients with the option to request and begin a consultation ...
(Date:4/24/2017)... CA (PRWEB) , ... April 24, 2017 , ... ... brain tumors are expected to be diagnosed globally; approximately 25,000 of them will ... are anticipating greater use of this type of healthcare model in the diagnosis ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
(Date:4/19/2017)... , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: ... Burton & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel ... Wright , Chief Executive Officer of the Company is scheduled to ... Richard Bear and the Chairman of the Board, ... ...
(Date:4/19/2017)... MOUNTAIN VIEW, Calif. , April 19, 2017 /PRNewswire/ ... that it will release financial results for the first ... May 3, 2017.  The Company,s management team will host ... / 5:30 p.m. ET. Investors interested in ... dialing (844) 707-0665 for domestic callers or (703) 326-3030 ...
Breaking Medicine Technology: